Biodegradable Polymers for Sustained Release of Polypeptides

  • F. G. Hutchinson
  • B. J. A. Furr
Part of the NATO ASI Series book series (NSSA, volume 125)


Recent years have seen major advances in genetic engineering and consequent bacterial production of many interesting and pharmacologically active polypeptides as well as improvements in techniques leading to total chemical synthesis of lower molecular weight peptides such as ‘Zoladex’ (ICI 118630; D-Ser (But)6-Azgly10-LHRH; ‘Zoladex’ is a trade mark, the property of Imperial Chemical Industries PLC). However the therapeutic and commercial potential of polypeptide drugs will only be realised if these advances are accompanied by dosage form design leading to practical and effective formulations.


Sustained Release Trade Mark Number Average Molecular Weight High Molecular Weight Polymer Lower Molecular Weight Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bohn, L., 1975, Compatible polymers, in: “Polymer Handbook”, 2nd Ed., J. Brandrup and E.H. Immergut, eds., John Wiley and Sons, New York.Google Scholar
  2. Furr, B.J.A. and Hutchinson, F.G., 1985, Biodegradable sustained release formulations of the LH-RH analogue ‘Zoladex’ for the treatment of hormone responsive tumours. “EORTC Genitourinary Group Monograph 2, Part A: Therapeutic principles in metastatic prostate cancer”, Alan R. Liss, Inc.Google Scholar
  3. Hutchinson, F.G., 1982, Continuous release pharmaceutical composition. European Patent Application 58481.Google Scholar
  4. Hutchinson, F.G. and Furr, B.J.A., 1985, Biodegradable polymers for the sustained release of peptides, Biochemical Society Transactions, 13: 520.PubMedGoogle Scholar
  5. Mitra, S., Van Dress, M., Anderson, J.M., Peterson, R.V., Gregonis, D. and Feijen, J., 1979, Pro-drug controlled release from poly glutamic acid, Polymer Preparations, American Chemical Society, Division Polymer Chemistry, 20: 32.Google Scholar
  6. Pitt, C.G. and Schindler, A., 1980, The design of controlled drug delivery systems based on biodegradable polymers, in: “Progress in contraceptive delivery systems”, E.S.E. Hafez and W.A.A. van Os, eds., MTP Press, Lancaster.Google Scholar
  7. Robinson, M.R.G., Denis, L., Mahler, C., Walker, K., Stitch, R. and Lunglmayr, G., 1985, An LH-RH analogue (‘Zoladex’) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly injections. Eur. J. Surg. Oncol., 11: 159.PubMedGoogle Scholar
  8. Sidman, K.R., Schwope, A.D., Steber, W.D. and Rudolph, S.E., 1981, Use of synthetic polypeptides in the preparation of biodegradable delivery systems for narcotic antagonists. NIDA Research Monographs, 28: 214.Google Scholar
  9. Walker, K.J., Turkes, A.O., Zwink, R., Beacock, C., Buck, A.C., Peeling, W.B. and Griffiths, K., 1984, Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LH-RH agonist ICI 118630. J. Endocrinol., 103: R1.PubMedCrossRefGoogle Scholar
  10. Wise, D.L., Fellman, T.D., Sanderson, J.E. and Wentworth, R.L., 1979, Lactic/glycolic acid polymers, in: “Drug carriers in biology and medicine”, G. Gregoriadis, eds, Academic Press, London.Google Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • F. G. Hutchinson
    • 1
  • B. J. A. Furr
    • 1
  1. 1.Pharmaceutical Department and Research Department, Pharmaceuticals DivisionImperial Chemical Industries PLCMacclesfield, CheshireUK

Personalised recommendations